Bitcoin Targets $180K in 2025, TYMIO Founder Predicts Supply Shock 
Dogecoin Soars 16.8% After Musk’s Alien Meme Shakes Up X: What It Means for Crypto 
Stellar Jumps 80% to $0.55 as Grayscale Trust Adds Millions—Is $1 Within Reach? 
Shiba Inu in Trouble? 33 Trillion SHIB Could Fall If $0.000022 Support Breaks 
Shiba Inu Sends Urgent Scam Alert Amid 12% Price Spike: Details Unveiled 
Bitcoin Slides to $95K, XRP Falls Over 10% Amid $495M Liquidation Wave Impacting 197K Traders 
Crypto Rules Shakeup: Trump-Tied SEC Candidate Hints at Clearer Path After Gensler’s Sudden Exit 
$18 XRP Prediction Gains Traction as Wave 3 Builds Toward $5 Surge Before 2024 
Senator Lummis Pushes for 1M BTC in US Reserve to Slash Debt, Preserve Dollar Dominance 
TikTok CEO Turns to Musk for Guidance Amid Trump Policy Concerns, WSJ Reports 
Xiaomi's Second Electric SUV to Challenge Tesla Model Y in Q1 2025, Report Reveals 
Shiba Inu Burn Rate Explodes 49,646% as SHIB Price Climbs 10% in Stunning Market Rally 
Solana Hits $262 ATH Amid $35M Whale Buys—Could $5,000 Be Next? 
OpenAI, Samsung Talks Signal a Major Shift for Galaxy Devices, Threatening Google’s AI Stronghold 
Ether Price Rises Despite $1.3B Whale Sell-Off, Targets $3,700 Breakout 
Apple Pushes Suppliers for Laptop OLED Displays, Hinting at Soon-to-Launch MacBook Pro Models 
SAN ANTONIO, Texas, May 03, 2017 -- bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030.
Titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” the EPO patent for bioAffinity’s platform test for early cancer detection will significantly increase bioAffinity’s intellectual property (IP) portfolio that currently consists of 43 awarded patents in 22 countries.
bioAffinity’s porphyrin-based CyPath® bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence that is detectable and measurable by flow cytometry. CyPath® Lung, bioAffinity’s initial product, is designed to be a highly accurate, non-invasive, early-stage lung cancer diagnostic for use by patients at risk for lung cancer.
“According to the World Health Organization, nearly 30 percent of European adults are smokers, and smoking among adolescents is on the rise,” bioAffinity President and CEO Maria Zannes said. “Tobacco use causes 16 percent of all deaths in the adult population over 30 years of age. We expect our CyPath® product to have a significant positive impact on early detection of lung cancer in the European Union.”
bioAffinity is focused on the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers. CyPath® Lung is a simple and cost-effective diagnostic, which will make it particularly valuable in countries with large populations and broad economic and social demographics.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
